AR and metabolic dysfunction-associated steatohepatitis: Although the potential function of HNF4G in HCC is unknown, a recent study revealed that HNF4G is a pioneer factor that reprograms the enhancer landscape at gastrointestinal genes and mediates androgen‐receptor therapy resistance in prostate cancer.[37] We thus propose that HNF4G/HNF4A may activate the expression of NASH‐associated genes via E‐P interaction, potentially leading to liver fibrosis/cirrhosis and HCC.